Directory
Mengying Hu Headshot

Professional Interests

The Hoo (Hu) research group focuses on the functional and mechanistic exploration of immune cell-derived extracellular vesicles (EVs) and EV-DNA in the context of diseases such as cancer and chronic inflammatory disorders. The ultimate goal is to inform the rationale design of non-viral gene therapies and diagnostic/prognostic tools. Specific research interests include functional and mechanistic exploration of immune cell-derived EVs and EV-DNA in disease settings such as cancer and auto-immune disorders, engineering core-shell lipid nanoparticles (LNPs) for the targeted delivery of nucleic acids, proteins, peptides, and small molecules to support therapeutic development for cancer, chronic inflammatory diseases, and autoimmune disorder and diagnostic/prognostic biomarker development based on circulating EVs and EV-DNA.

Biography

Dr. Hu earned her PhD in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill, where she built the framework for the design and optimization of core-supported lipid nanoparticles for delivering nucleic acid therapeutics. She then completed postdoctoral training at Weill Cornell Medical College as a TL1 scholar in the Clinical and Translational Science Program, where she uncovered the immune-boosting activities of T cell-derived EVs and EV-DNA. Her work has since expanded to encompass translational research, including but not limited to identifying EV biomarkers for early detection, cancer progression, and treatment responses.

Education

  • 2019, PhD Pharmaceutical Sciences, University of North Carolina at Chapel Hill
  • 2016, MS Pharmaceutical Sciences, Zhejiang University, China
  • 2013, BS Pharmaceutical Sciences, Zhejiang University of Technology, China

Honors

  • 2022, CTSC TL1 Training Award
  • 2019, Baxter Young Investigator Award

Publications